M
M. R. K. Alley
Researcher at Anacor Pharmaceuticals Inc.
Publications - 18
Citations - 1664
M. R. K. Alley is an academic researcher from Anacor Pharmaceuticals Inc.. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 12, co-authored 13 publications receiving 1417 citations.
Papers
More filters
Journal ArticleDOI
An Antifungal Agent Inhibits an Aminoacyl-tRNA Synthetase by Trapping tRNA in the Editing Site.
Fernando Rock,Weimin Mao,A. D. Yaremchuk,M. A. Tukalo,Thibaut Crépin,Huchen Zhou,Yong Kang Zhang,Vincent Hernandez,Tsutomu Akama,Stephen J. Baker,Jacob J. Plattner,Lucy Shapiro,Susan A. Martinis,Stephen J. Benkovic,Stephen Cusack,M. R. K. Alley +15 more
TL;DR: The broad-spectrum antifungal 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), in development for the treatment of onychomycosis, inhibits yeast cytoplasmic leucyl-tRNA synthetase by formation of a stable tRNALeu-AN 2690 adduct in the editing site of the enzyme.
Journal ArticleDOI
Discovery of a New Boron-Containing Antifungal Agent, 5-Fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the Potential Treatment of Onychomycosis
Stephen J. Baker,Yong-Kang Zhang,Tsutomu Akama,Agnes Lau,Huchen Zhou,Vincent Hernandez,Weimin Mao,M. R. K. Alley,Virginia Sanders,Jacob J. Plattner +9 more
TL;DR: A structure-activity relationship investigation led to the discovery of a boron-containing small molecule, 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), which is currently in clinical trials for onychomycosis topical treatment.
Journal ArticleDOI
Discovery of a Novel Class of Boron-Based Antibacterials with Activity against Gram-Negative Bacteria
Vincent Hernandez,Thibaut Crépin,Andrés Palencia,Stephen Cusack,Tsutomu Akama,Stephen J. Baker,Wei Bu,Lisa Feng,Yvonne Freund,Liang Liu,Maliwan Meewan,Manisha Mohan,Weimin Mao,Fernando Rock,Holly Sexton,Anita Sheoran,Yanchen Zhang,Yong-Kang Zhang,Yasheen Zhou,James A. Nieman,Mahipal Reddy Anugula,Keramane El Mehdi,Kingsley Savariraj,D. Shekhar Reddy,Rashmi Sharma,Rajendra Subedi,Rajeshwar Singh,Ann O'Leary,Nerissa L. Simon,Peter L. De Marsh,Shazad Mushtaq,Marina Warner,David M. Livermore,David M. Livermore,M. R. K. Alley,Jacob J. Plattner +35 more
TL;DR: A new boron-based antibiotic class, the aminomethylbenzoxaboroles, which inhibit bacterial leucyl-tRNA synthetase and have activity against Gram-negative bacteria by largely evading the main efflux mechanisms in Escherichia coli and Pseudomonas aeruginosa is developed.
Journal ArticleDOI
A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue.
Ebere Sonoiki,Ebere Sonoiki,Caroline L. Ng,Marcus C. S. Lee,Denghui Guo,Yong Kang Zhang,Yasheen Zhou,M. R. K. Alley,Vida Ahyong,Laura M. Sanz,Maria Jose Lafuente-Monasterio,Chen Dong,Patrick G. Schupp,Jiri Gut,Jenny Legac,Roland A. Cooper,Francisco-Javier Gamo,Joseph L. DeRisi,Yvonne Freund,David A. Fidock,Philip J. Rosenthal +20 more
TL;DR: The results identify the pre-mRNA processing factor PfCPSF3 as a promising antimalarial drug target.
Journal ArticleDOI
Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656)
Xianfeng Li,Vincent Hernandez,Fernando Rock,Wai Choi,Yvonne Mak,Manisha Mohan,Weimin Mao,Yasheen Zhou,Eric E. Easom,Jacob J. Plattner,Wuxin Zou,Esther Pérez-Herrán,Ilaria Giordano,Alfonso Mendoza-Losana,Carlos Alemparte,Joaquín Rullas,Iñigo Angulo-Barturen,Sabrinia D. Crouch,Fátima Ortega,David Barros,M. R. K. Alley +20 more
TL;DR: GSK3036656, a novel series of 3-aminomethyl 4-halogen benzoxaboroles as Mycobacterium tuberculosis (Mtb) leucyl-tRNA synthetase (LeuRS) inhibitors, exhibits remarkable PK profiles and efficacy against Mtb in mouse TB infection models with superior tolerability over initial leads.